Federal Register / Vol. 75, No. 197 / Wednesday, October 13, 2010 / Notices 62843 

08869, 908–526–2400/800–437–4986, 

(Formerly: Roche Biomedical 

Laboratories, Inc.) 

Laboratory Corporation of America 

Holdings, 1904 Alexander Drive, 

Research Triangle Park, NC 27709, 

919–572–6900/800–833–3984, 

(Formerly: LabCorp Occupational 

Testing Services, Inc., CompuChem 

Laboratories, Inc.; CompuChem 

Laboratories, Inc., A Subsidiary of 

Roche Biomedical Laboratory; Roche 

CompuChem Laboratories, Inc., A 

Member of the Roche Group). 

Laboratory Corporation of America 

Holdings, 1120 Main Street, 

Southaven, MS 38671, 866–827–8042/ 

800–233–6339, (Formerly: LabCorp 

Occupational Testing Services, Inc.; 

MedExpress/National Laboratory 

Center). 

LabOne, Inc. d/b/a Quest Diagnostics, 

10101 Renner Blvd., Lenexa, KS 

66219, 913–888–3927/800–873–8845, 

(Formerly: Quest Diagnostics 

Incorporated; LabOne, Inc.; Center for 

Laboratory Services, a Division of 

LabOne, Inc.,). 

Maxxam Analytics*, 6740 Campobello 

Road, Mississauga, ON, Canada L5N 

2L8, 905–817–5700, (Formerly: 

Maxxam Analytics Inc., NOVAMANN 

(Ontario), Inc.) 

MedTox Laboratories, Inc., 402 W. 

County Road D, St. Paul, MN 55112, 

651–636–7466/800–832–3244. 

MetroLab-Legacy Laboratory Services, 

1225 NE 2nd Ave., Portland, OR 

97232, 503–413–5295/800–950–5295. 

Minneapolis Veterans Affairs Medical 

Center, 

Forensic Toxicology Laboratory, 1 

Veterans Drive, Minneapolis, MN 

55417, 612–725–2088. 

National Toxicology Laboratories, Inc., 

1100 California Ave., Bakersfield, CA 

93304, 661–322–4250/800–350–3515. 

One Source Toxicology Laboratory, Inc., 

1213 Genoa-Red Bluff, Pasadena, TX 

77504, 888–747–3774, (Formerly: 

University of Texas Medical Branch, 

Clinical Chemistry Division; UTMB 

Pathology-Toxicology Laboratory). 

Pacific Toxicology Laboratories, 9348 

DeSoto Ave., Chatsworth, CA 91311, 

800–328–6942, (Formerly: Centinela 

Hospital Airport Toxicology 

Laboratory). 

Pathology Associates Medical 

Laboratories, 110 West Cliff Dr., 

Spokane, WA 99204, 509–755–8991/ 

800–541–7891x7. 

Phamatech, Inc., 10151 Barnes Canyon 

Road, San Diego, CA 92121, 858–643– 

5555. 

Quest Diagnostics Incorporated, 1777 

Montreal Circle, Tucker, GA 30084, 

800–729–6432, (Formerly: SmithKline 

Beecham Clinical Laboratories; 

SmithKline Bio-Science Laboratories). 

Quest Diagnostics Incorporated, 400 

Egypt Road, Norristown, PA 19403, 

610–631–4600/877–642–2216, 

(Formerly: SmithKline Beecham 

Clinical Laboratories; SmithKline BioScience Laboratories). 

Quest Diagnostics Incorporated, 8401 

Fallbrook Ave., West Hills, CA 91304, 

800–877–2520, (Formerly: SmithKline 

Beecham Clinical Laboratories). 

S.E.D. Medical Laboratories, 5601 Office 

Blvd., Albuquerque, NM 87109, 

505–727–6300/800–999–5227. 

South Bend Medical Foundation, Inc., 

530 N. Lafayette Blvd., South Bend, 

IN 46601, 574–234–4176 x1276. 

Southwest Laboratories, 4625 E. Cotton 

Center Boulevard, Suite 177, Phoenix, 

AZ 85040, 602–438–8507/800–279– 

0027. 

St. Anthony Hospital Toxicology 

Laboratory, 1000 N. Lee St., 

Oklahoma City, OK 73101, 405–272– 

7052. 

STERLING Reference Laboratories, 2617 

East L Street, Tacoma, Washington 

98421, 800–442–0438. 

Toxicology & Drug Monitoring 

Laboratory, University of Missouri 

Hospital & Clinics, 301 Business Loop 

70 West, Suite 208, Columbia, MO 

65203, 573–882–1273. 

Toxicology Testing Service, Inc., 5426 

N.W. 79th Ave., Miami, FL 33166, 

305–593–2260. 

U.S. Army Forensic Toxicology Drug 

Testing Laboratory, 2490 Wilson St., 

Fort George G. Meade, MD 20755– 

5235, 301–677–7085. 

* The Standards Council of Canada 

(SCC) voted to end its Laboratory 

Accreditation Program for Substance 

Abuse (LAPSA) effective May 12, 1998. 

Laboratories certified through that 

program were accredited to conduct 

forensic urine drug testing as required 

by U.S. Department of Transportation 

(DOT) regulations. As of that date, the 

certification of those accredited 

Canadian laboratories will continue 

under DOT authority. The responsibility 

for conducting quarterly performance 

testing plus periodic on-site inspections 

of those LAPSA-accredited laboratories 

was transferred to the U.S. HHS, with 

the HHS’ NLCP contractor continuing to 

have an active role in the performance 

testing and laboratory inspection 

processes. Other Canadian laboratories 

wishing to be considered for the NLCP 

may apply directly to the NLCP 

contractor just as U.S. laboratories do. 

Upon finding a Canadian laboratory to 

be qualified, HHS will recommend that 

DOT certify the laboratory (Federal 

Register, July 16, 1996) as meeting the 

minimum standards of the Mandatory 

Guidelines published in the Federal 

Register on April 30, 2010 (75 FR 

22809). After receiving DOT 

certification, the laboratory will be 

included in the monthly list of HHScertified laboratories and participate in 

the NLCP certification maintenance 

program. 

Dated: October 6, 2010. 

Elaine Parry, 

Director, Office of Management, Technology, 

and Operations, SAMHSA. 

[FR Doc. 2010–25705 Filed 10–12–10; 8:45 am] 

BILLING CODE 4160–20–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Health Resources and Services 

Administration 

Advisory Council on Blood Stem Cell 

Transplantation; Notice of Meeting 

In accordance with section 10(a)(2) of 

the Federal Advisory Committee Act 

(Pub. L. 92–463), notice is hereby given 

of the following meeting: 

Name: Advisory Council on Blood Stem 

Cell Transplantation. 

Date and Times: November 15, 2010, 8:30 

a.m. to 4:30 p.m. 

Place: Hyatt Regency Bethesda, One 

Bethesda Metro Center, Bethesda, Maryland 

20814. 

Status: The meeting will be open to the 

public. 

Purpose: Pursuant to Public Law 109–129, 

42 U.S.C. 274k (section 379 of the Public 

Health Service Act, as amended) the 

Advisory Council on Blood Stem Cell 

Transplantation (ACBSCT) advises the 

Secretary of HHS and the Administrator, 

HRSA, on matters related to the activities of 

the C.W. Bill Young Cell Transplantation 

Program (Program) and the National Cord 

Blood Inventory (NCBI) Program. 

Agenda: The Council will hear reports 

from five ACBSCT Work Groups: Cord Blood 

Bank Collections, Realizing the Potential of 

Cord Blood, Scientific Factors Necessary to 

Define a Cord Blood Unit as High Quality, 

Cord Blood Thawing and Washing, and 

Access to Transplantation. The Council also 

will hear presentations and discussions on 

the following topics: Arizona reimbursement 

concerns for Medicaid beneficiaries, 

Myelodysplastic Syndromes (MDS) coverage, 

Medicare reimbursement for costs for 

allogeneic or autologous transplants, 

legislative reauthorization and 

appropriations bills, and Program 

performance measures. Agenda items are 

subject to change as priorities indicate. 

After the presentations and Council 

discussions, members of the public will have 

an opportunity to provide comments. 

Because of the Council’s full agenda and the 

timeframe in which to cover the agenda 

topics, public comment will be limited. All 

public comments will be included in the 

mstockstill on DSKH9S0YB1PROD with NOTICES

62844 Federal Register / Vol. 75, No. 197 / Wednesday, October 13, 2010 / Notices 

record of the ACBSCT meeting. Meeting 

summary notes will be made available on the 

HRSA’s Program Web site at http:// 

bloodcell.transplant.hrsa.gov/ABOUT/ 

Advisory_Council/index.html. 

Those planning to attend are requested to 

register in advance. The draft meeting agenda 

and a registration form are available on the 

HRSA’s Program Web site at http:// 

bloodcell.transplant.hrsa.gov/ABOUT/ 

Advisory_Council/index.html. 

Registration also can be completed 

electronically at http://www.acbsct.com or 

submitted by facsimile to Lux Consulting 

Group, Inc., the logistical support contractor 

for the meeting, at fax number (301) 585– 

7741 Attn: Tristan Alexander. Individuals 

without access to the Internet who wish to 

register may call Tristan Alexander at (301) 

585–1261. 

FOR FURTHER INFORMATION CONTACT: 

Patricia Stroup, Executive Secretary, 

Healthcare Systems Bureau, Health 

Resources and Services Administration, 

5600 Fishers Lane, Room 12C–06, 

Rockville, Maryland 20857; telephone 

(301) 443–1127. 

Dated: October 6, 2010. 

Wendy Ponton, 

Director, Office of Management. 

[FR Doc. 2010–25646 Filed 10–12–10; 8:45 am] 

BILLING CODE 4165–15–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Advisory Committee to the Director 

(ACD), Centers for Disease Control and 

Prevention (CDC) 

In accordance with section 10(a)(2) of 

the Federal Advisory Committee Act 

(Pub. L. 92–463), the CDC announces 

the following meeting of the 

aforementioned committee: 

Time and Date: 8:30 a.m.–3 p.m., October 

28, 2010. 

Place: CDC, 1600 Clifton Road, NE., 

Building 21, Rooms 1204 A/B, Atlanta, 

Georgia 30333. 

Status: Open to the public, limited only by 

the space available. The meeting room 

accommodates approximately 50 people. The 

public is welcome to participate during the 

public comment period. The public comment 

period is tentatively scheduled for 2:30 to 

2:45 p.m. 

Purpose: The committee will provide 

advice to the CDC Director on strategic and 

other broad issues facing CDC. 

Matters to be Discussed: The ACD, CDC 

will receive updates from the Global 

Workgroup; State, Tribal, Local and 

Territorial Workgroup; Surveillance and 

Epidemiology Workgroup; and the Policy 

Workgroup. The Ethics Subcommittee and 

National Biosurveillance Advisory 

Subcommittee will provide updates on their 

current activities. 

Agenda items are subject to change as 

priorities dictate. 

Contact Person for More Information: 

Carmen Villar, M.S.W., Designated Federal 

Officer, ACD, CDC, 1600 Clifton Road, NE., 

M/S D–14, Atlanta, Georgia 30333. 

Telephone 404/639–7000. E-mail: 

GHickman@cdc.gov. The deadline for 

notification of attendance is October 25, 

2010. 

The Director, Management Analysis and 

Services Office, has been delegated the 

authority to sign Federal Register notices 

pertaining to announcements of meetings and 

other committee management activities, for 

both the Centers for Disease Control and 

Prevention and the Agency for Toxic 

Substances and Disease Registry. 

Dated: October 5, 2010. 

Elaine L. Baker, 

Director, Management Analysis and Services 

Office, Centers for Disease Control and 

Prevention. 

[FR Doc. 2010–25703 Filed 10–12–10; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

[Docket No. FDA–2010–N–0001] 

Innovations in Technology for the 

Treatment of Diabetes: Clinical 

Development of the Artificial Pancreas 

(an Autonomous System); Public 

Workshop 

AGENCY: Food and Drug Administration, 

HHS. 

ACTION: Notice of public workshop. 

The Food and Drug Administration 

(FDA) and the National Institutes of 

Health (NIH) are announcing a public 

workshop entitled ‘‘Innovations in 

Technology for the Treatment of 

Diabetes: Clinical Development of the 

Artificial Pancreas (an Autonomous 

System).’’ The topics to be discussed are 

the current state of device systems for 

autonomous systems for the treatment of 

diabetes mellitus, the challenges in 

developing this expert system using 

existing technology, a discussion of the 

clinical expectations and success 

criteria for these systems, and a 

discussion of development plans for the 

transition of this device system toward 

an outpatient setting. 

Date and Time: The public workshop 

will be held on November 10, 2010, 

from 8 a.m. to 5 p.m. Persons interested 

in attending this meeting must register 

by 5 p.m. on November 3, 2010. 

Location: The meeting will be held at 

the Hilton Washington, DC North/ 

Gaithersburg Hotel, 620 Perry Pkwy., 

Gaithersburg, MD 20877. 

Contact: Charles Zimliki, Food and 

Drug Administration, Center for Devices 

and Radiological Health (CDRH), 10903 

New Hampshire Ave., Bldg. 66, rm. 

2556, Silver Spring, MD 20993–0002, 

301–796–6297, Fax: 301–847–8109, email: Charles.Zimliki@fda.hhs.gov. 

Registration: Registration is free and 

will be on a first-come, first-served 

basis. To register for the public 

workshop, webinar or onsite attendance, 

please visit the following Web site: 

http://www.fda.gov/MedicalDevices/ 

NewsEvents/WorkshopsConferences/ 

ucm226251.htm (select the appropriate 

meeting from the list). Please provide 

complete contact information for each 

attendee, including name, title, 

affiliation, address, e-mail, and 

telephone number. For those without 

Internet access, please call Victoria 

Wagman at 301–796–6581 to register. 

Registration requests should be received 

by 5 p.m. on November 3, 2010. Early 

registration is recommended because 

seating is limited and therefore FDA/ 

NIH may limit the number of 

participants from each organization. If 

time and space permits, onsite 

registration on the day of the public 

meeting will be provided beginning at 7 

a.m. 

If you need special accommodations 

due to a disability, please contact Susan 

Monahan (e-mail: 

Susan.Monahan@fda.hhs.gov) at least 7 

days in advance. 

SUPPLEMENTARY INFORMATION: 

I. Background 

CDRH has undertaken an initiative to 

proactively facilitate medical device 

innovation to address unmet public 

health needs. As part of this initiative, 

CDRH with NIH have focused on the 

development of the artificial pancreas 

(or Autonomous System) for the 

treatment of diabetes mellitus. An 

artificial pancreas is a medical device 

that links a glucose monitor to an 

insulin infusion pump where the pump 

automatically takes action (using a 

control algorithm) based upon the 

glucose monitor reading. As control 

algorithms can vary significantly, there 

are a variety of artificial pancreas 

systems currently under development. 

These systems can range from low 

glucose suspend, to control-to-range, to 

control-to-target, to bihormonal control 

where each device has different 

purposes or intended uses for 

controlling blood sugars. In addition, 

most research in this area uses existing 

medical device technology, which might 

limit the performance and evaluation of 

these systems. Given these device 

limitations, preliminary research has 

focused on evaluating these systems in 

mstockstill on DSKH9S0YB1PROD with NOTICES